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The human genome project reached a major milestone ear-
lier this year, with the completion of a rough draft of the se-
quence (Pennisi, 2000). An accessible catalog of all human
genes could greatly accelerate the pace of breakthroughs in
medical research by allowing global analyses of gene ex-
pression changes in a variety of developmental and patho-
logical states. However, it has never been clear whether
these types of analyses could be efficiently performed, or
whether significant sets of important data would emerge
from the study of large sets of genes. Many diseases arise
from single gene mutations in which the corresponding pro-
tein products are known. Would knowledge of global gene
expression changes add to our existing understanding of
these monogenic disorders or lead to the development of
treatments? A paper in this issue provides a test of these
questions and suggests that large scale gene expression pro-
filing can contribute greatly to an understanding of mono-
genic disease mechanisms, may simplify diagnosis of genetic
diseases, and could eventually provide important clues to
assist with the development of novel molecular therapies.
Chen et al. (2000) report a survey of gene expression
changes in two types of muscular dystrophy whose primary
gene defect was known (Chen et al., 2000). The results dem-
onstrate both the power and value of this type of analysis
while providing a number of interesting insights into the un-
derlying disease pathologies. This work also serves as a
model for the application of this approach to other mono-
genic disorders. Chen et al. have carefully considered ap-
proaches to overcoming many of the inherent difficulties in
analyzing gene expression changes from diseased tissues,
and provide a preliminary check of some of the more in-
triguing observations of altered mRNA levels by immu-
nolocalization studies of the corresponding proteins. To-
gether, these observations have confirmed some previously
known features of muscular dystrophies, have uncovered
several novel alterations that may contribute to disease pa-
thology, and have revealed interesting differences between
two similar forms of dystrophy that may be as important to
understanding the disease pathogenesis as is knowledge of
the primary defects that initiate muscle cell degeneration.
The focus of the work by Chen et al. (2000) was on two
related diseases, Duchenne and limb–girdle muscular dys-
trophies (DMD and LGMD)
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. DMD is the most common
form of the disease and arises from defects in the dystro-
phin gene (Monaco et al., 1986). Dystrophin is an enor-
mous cytoskeletal protein that links the muscle cytoskele-
ton to the extracellular matrix (Koenig et al., 1988; Ervasti
and Campbell, 1993). This linkage facilitates force trans-
 
duction from the contractile apparatus to the connec-
tive tissue surrounding muscle fibers, stabilizing the sar-
colemma and minimizing contraction induced injuries
(Petrof et al., 1993; Lynch et al., 2000). Dystrophin works
by interacting with a large number of integral and periph-
eral membrane proteins known as the dystrophin glyco-
protein complex (DGC), which includes four members
encoded by the sarcoglycan gene family (Ibraghimov-
Beskrovnaya et al., 1992; Ozawa et al., 1995). Mutations in
any of the sarcoglycan genes lead to different types of
LGMD, which are distinct, yet similar diseases to DMD
(Bönnemann et al., 1995; Bushby, 1999).
 
Most models for the function of the DGC imply that mu-
tation of either dystrophin or one of the sarcoglycans
should render the DGC nonfunctional and lead to essen-
tially identical phenotypes, yet a surprising number of dif-
ferences have been observed. Some groups have speculated
that the sarcoglycans and other DGC members such as the
syntrophin and dystrobrevin family members could play
auxiliary roles in maintaining normal muscle function by
regulating or localizing signal transduction molecules.
These signaling pathways would presumably help muscle
cells adapt to the myriad forms of stress imposed by muscle
activity. However, despite extensive analysis in transgenic
mice and induced knockout models for the sarcoglycans,
the nature and importance of these signals remains obscure
(Hack et al., 1998; Grady et al., 1999; Crawford et al., 2000).
 
Understanding the precise function of the DGC may fa-
cilitate development of an efficient therapy for the muscu-
lar dystrophies. Despite knowledge of the primary genetic
defects, the mechanisms that lead to muscle cell dysfunc-
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tion and death in the muscular dystrophies are poorly un-
derstood. For example, how does the absence of dystro-
phin lead to instability of the sarcolemma? Why do
different disruptions of the DGC lead to different manifes-
tations of the dystrophic process? The overall phenotypic
manifestations of these diseases presumably result from a
combination of muscle fiber necrosis, incomplete regener-
ation, infiltration of damaged muscle with immune effector
cells, perturbed metabolic capacity, reduced blood supply
to exercising muscle, activation of apoptotic pathways, and
many other unknown processes. Developing a compete un-
derstanding of these multiple pathological events could
help guide new types of therapies, as well as provide refer-
ence points for assessing the effectiveness of therapeutic
intervention. For these reasons, the global gene expression
analysis of Chen et al. (2000) plays an especially important
role, by providing the first overall picture of the gene ex-
pression state of dystrophic muscle tissue.
Chen et al. (2000) provide a significant amount of clarity to
the overall pattern of gene expression in dystrophic muscle
because of their elaborate and well controlled approach. A
direct comparison between a dystrophic and a normal muscle
sample is difficult to interpret due to phenotypic variations
within an individual muscle biopsy, as well as patient-specific
differences arising from genetic variability. In addition, com-
parison of samples only from DMD patients and normal con-
trols might reveal both specific and nonspecific alterations,
making it difficult to identify the most important differences.
Chen et al. (2000) solved some of these dilemmas by analyz-
ing pooled samples from multiple controls in parallel with
pooled samples from multiple patients that had either DMD,
or LGMD resulting from mutations in the alpha-sarcoglycan
gene. To reduce the problems that might arise from varia-
tions within a given biopsy and provide independent confir-
mation of the data sets, each muscle specimen was divided in
half before preparing pooled sets for parallel processing.
Pooled probes made from the sample sets were analyzed for
gene expression by hybridization to the Affymetrix Hu-
GeneFL microarray that contains sequences from 
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6,000 hu-
man genes. Sophisticated data analysis tools were then used
to compare each result and identify trends. The authors fo-
cused on several types of changes. Initially, genes whose ex-
pression was consistently elevated or reduced in either type
of dystrophy were identified. Next, genes whose expression
was consistently altered only in one of the two types of dys-
trophy were identified. As a result, the authors derived a list
of genes whose products were likely to be altered in any gen-
eral dystrophic process and those that might contribute to
specific features of a single form of muscular dystrophy. Fi-
nally, a select subset of the more interesting and accessible al-
terations was confirmed by immunologic analysis of muscle
biopsies. While this enormous data set will require a great
deal of further analysis, a variety of interesting and novel
trends have already emerged.
An initial observation from the data sets is that many
secondary features of the disease, which had been hinted
at in earlier studies were confirmed and extended, such as
a generalized metabolic crisis manifested by a significant
reduction in the expression of many nuclear-encoded mi-
tochondrial genes. Upregulated gene expression was also
observed for many cell surface and extracellular proteins,
perhaps reflecting the widespread fibrosis and mononu-
clear cell infiltrates seen in dystrophies. In addition, a
number of calcium-regulated signaling molecules were
downregulated, potentially providing new insights into
pathways affected by the altered calcium homeostasis that
results from ruptures in the sarcolemma membrane. Per-
haps more importantly, a number of novel observations
were apparent that should inspire increased efforts to ex-
amine the consequence of these changes on the dystro-
phies. A few examples of the many novel observations
from the gene expression analysis include reduced levels
of the protein kinase ERK6 and the protein phosphatase
pTPH1 in DMD, but not in LGMD. The expression of nu-
merous genes involved in cell growth and signaling was
also upregulated. Intriguingly, several markers for acti-
vated dendritic cells were elevated in dystrophic samples,
supporting a role for immune effector cells altering the mi-
croenvironment of dystrophic muscle.
One of the more striking observations made by Chen et
al
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(2000) is that dystrophic muscle may exist in a general-
ized state of incomplete differentiation. Widespread ele-
vated levels of embryonic muscle isoforms for both myosin
heavy chain and alpha-actin support the idea of a general-
ized state of incomplete differentiation, and the observed
changes can not be accounted for solely by the number of
actively regenerating fibers. Reduced mRNA levels for
the alpha subunit of the acetylcholine receptor could con-
tribute to neuromuscular junction structural abnormalities
seen in DMD and may inhibit complete muscle matura-
tion by contributing to a functional denervation of the
muscle (Rafael et al., 2000). The authors also provide evi-
dence for a process by which cells in dystrophic muscle tis-
sue might be undergoing a dedifferentiation into alternate
lineages such as bone and connective tissue precursors.
Despite the enormous wealth of information produced by
Chen et al. (2000), it is clear that many additional observa-
tions remain to be mined from these data sets. Further in-
terpretation of the emerging trends will also be aided by ad-
ditional studies on biopsies obtained at different stages of
disease progression and from additional forms of muscular
dystrophy. However, the present data have already pro-
vided numerous new insights that will immediately aid stud-
ies of the disease pathogenesis. These data should also lead
to a variety of new targets to treat secondary pathological
features of the diseases, and may well provide a generalized
method to monitor the efficacy of such interventions, which
might be used either singly or in combination with cell and
gene based therapies (Hartigan-O’Connor and Chamber-
lain, 2000). Finally, as Chen et al. (2000) note, these ap-
proaches may also serve as a basis for differential diagnosis
of the many types of muscular dystrophy by enabling test of
specific molecule signatures associated with each individual
primary genetic defect. This convergence of the human ge-
nome project and molecular medicine may well be a critical
factor in finding a cure for muscular dystrophy.
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